Robust immunogenicity to the H3N2 component of influenza A vaccine in primary Sjögren syndrome.
Sandra Gofinet PasotoEduardo Ferreira BorbaFrancisco Fellipe Claudino FormigaTatiana do Nascimento PedrosaNadia Emi AikawaMarilda Agudo Mendonça Teixeira de SiqueiraArtur Silva Vidal CapãoAdriana Coracini Tonacio de ProençaRicardo FullerEmily Figueiredo Neves YukiElaine Pires LeonVictor Adriano de Oliveira MartinsMarta Heloisa LopesAlberto José da Silva DuarteClovis Artur Almeida da SilvaEloisa BonfaPublished in: Clinical rheumatology (2023)
gov: #NCT03540823. Key Points • This prospective study demonstrated a robust pre- and post-vaccination immunogenicity to influenza A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus in primary Sjögren's syndrome (pSS). • This high immunogenicity pattern may be related to pre-existing immunization, or else it is related to immunogenicity differences of each strain. • This vaccine had an adequate safety profile in pSS, with no impact on disease activity.